PUMA BIOTECHNOLOGY, INC. Available-for-sale Securities, Amortized Cost Basis
PUMA BIOTECHNOLOGY, INC. (PBYI) had Available-for-sale Securities, Amortized Cost Basis of $112.85 million as of 2018-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-11-05
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $112.85M.
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $112.25M.
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $78.55M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $67.75M; Available-for-sale Securities, Amortized Cost Basis as first filed $81.70M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2018-09-30 | $112.85M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $112.25M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $78.55M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $67.75M 10-Q · filed 2018-11-05 | $81.70M 10-K · filed 2018-03-09 |
| 2017-09-30 | $95.53M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $143.22M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $185.83M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $223.54M 10-K · filed 2018-03-09 | $223.53M 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |